“…Furthermore, Sala et al, Berg Early in this pandemic, it was also suggested by a few studies that latent tuberculosis (LTB) could mitigate COVID-19 morbidity and mortality. 11,16,17,18,19,20,21, Some tested TB prevalence 16,20,22 as a proxy for LTB, while others considered LTB estimates that might cross-react with BCG and other mycobacteria. Other studies considered positivity in the TST/interferon-gamma release assay (IGRA) as a measure of the potential protective effect of the resident populations' exposure to Mycobacterium spp., whether from BCG vaccination or as a result of exposure to environmental mycobacteria.…”